1. Evaluation of mrkD, pgaC and wcaJ as biomarkers for rapid identification of K. pneumoniae biofilm infections from endotracheal aspirates and bronchoalveolar lavage.
- Author
-
Devanga Ragupathi, Naveen Kumar, Muthuirulandi Sethuvel, Dhiviya Prabaa, Ganesan, Anju, Murugan, Dhivya, Baskaran, Ashtawarthani, Wannigama, Dhammika Leshan, Monk, Peter N., Karunakaran, Esther, and Veeraraghavan, Balaji
- Subjects
- *
EMERGING infectious diseases , *DRUG resistance in bacteria , *KLEBSIELLA pneumoniae , *DRUG resistance in microorganisms , *REVERSE transcriptase polymerase chain reaction , *NOSOCOMIAL infections - Abstract
Klebsiella pneumoniae has been identified as one of the most important opportunistic pathogens responsible for nosocomial infections. Antibiotic resistance and the ability to form biofilms are the two main factors involved in the persistence of infections. Conventional detection methods involve culture isolation and identification followed by biofilm assay that takes 48–72 h. Timely detection of biofilm-forming resistant pathogens is essential to appropriately treat the infection with the right dose and combinations. The present study focuses on evaluating an RT-PCR panel using mrkD, pgaC, and wcaJ genes to screen for biofilm-forming K. pneumoniae from ETA/BAL specimens. The assay accurately identified K. pneumoniae harboring samples with a limit of detection of 1 ng/µl total RNA. Representative culture-negative-PCR-positive samples were subjected to metagenomics which identified K. pneumoniae reads in these samples confirming the specificity of RT-PCR. mrkD and pgaC act as K. pneumoniae specific identification whereas wcaJ acts as a negative marker for biofilm-forming K. pneumoniae. In addition, RT-PCR results correlated well with the phenotypic biofilm-forming assay. This RT-PCR assay is the first of its kind for rapid identification of biofilm-forming K. pneumoniae. The result of this study highlights that the rapid detection of K. pneumoniae biofilms based on the RT-PCR results coupled with clinical conditions would be appropriate to treat emerging infections or to prevent re-infections in clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF